Zev A. Wainberg on Muck Rack

Zev A. Wainberg

Los Angeles
As seen in: PeerView Gastroenterology CME/CNE/CPE Audio Podcast, Nature, PLOS, The Oncologist, MDPI, Medscape, The New England Journal of Medicine, The Lancet, Healio, HemOnc Today, NewsBreak and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zev A.

Contact Zev A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

|
By Eileen M. O’Reilly, Zev A. Wainberg, Brian Wolpin
| nej.md
Notes This article was published on May 31, 2026, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by Revolution Medicines. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Open in Who Shared Issue with article?

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

|
By Eileen M. O’Reilly, Zev A. Wainberg, Brian Wolpin
| The New England Journal of Medicine Verified
Notes This article was published on May 31, 2026, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by Revolution Medicines. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Open in Who Shared Issue with article?

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

|
By Zev A. Wainberg, Gulam A. Manji, Nathan Bahary, Susanna V Ulahannan, Shubham Pant, David R. Spigel, Nataliya V. Uboha, Paul E. Oberstein, Anwaar Saeed, Ji Kim, Ning WANG, Ben Weeder, Karim Mrouj, Jennifer Scott, Daniel DiRenzo, Matthew Walters, Wilson Wu, Soonweng Cho, Eileen M. O’Reilly, Brandon Beagle, Shravani Shitole, Lisa G. Ensign, Angelo Kaplan, Omar Kabbarah
| Nature Verified
Abstract Quemliclustat potently inhibits CD73, a key enzyme producing immunosuppressive adenosine. In a phase 1b trial (ARC-8), we evaluated safety and efficacy of quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab (anti-programmed cell death protein 1 (PD-1)) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
Open in Who Shared Issue with article?
See all 29 licensed articles (74 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified